Cost-effectiveness analysis of HPV vaccination alongside cervical cancer screening programme in Slovenia

European Journal of Public Health

Volumn 20, Issue 4, 2010, Pages 415-421

  Obradovic, Marko ^a   Mrhar, Ales ^a   Kos, Mitja ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

cervical cancer screening; cost effectiveness; human papillomavirus; natural history model; vaccine

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COHORT ANALYSIS; COST BENEFIT ANALYSIS; EARLY DIAGNOSIS; ECONOMICS; FEMALE; HEALTH CARE QUALITY; HUMAN; INCIDENCE; MASS SCREENING; MIDDLE AGED; PROBABILITY; SLOVENIA; UTERINE CERVIX TUMOR;

ADOLESCENT; ADULT; AGED; CHILD; COHORT STUDIES; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; INCIDENCE; MARKOV CHAINS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRUS VACCINES; PROGRAM EVALUATION; SLOVENIA; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 77955040024     PISSN: 11011262     EISSN: 1464360X     Source Type: Journal    
DOI: 10.1093/eurpub/ckp208     Document Type: Article

References (37)

1. World Health Organisation (WHO). The global burden of disease-2004 update. Available at: http://www.who.int/healthinfo/global-burden-disease/ GBD-report-2004update-full.pdf (last accessed 21 December 2008).
2. Waggoner SE. Cervical cancer. Lancet 2003;361:2217-2225
3. Insinga RP, Dasbach EJ, Elbasha EH. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics 2005;23:1107-1122
4. Bosch FX, de Sanjose S. Chapter 1: Human papillomavirus and cervical cancer-burden and assessment of causality. J Natl Cancer Inst Monogr 2003;31:3-13.
5. International Agency for Research on Cancer (IARC). GLOBOCAN 2002. Available at: http://www-dep.iarc.fr/ (last accessed 12 December 2008).
6. National screening programme ZORA. Available at: http://www.onko-i.si/ zora/ (last accessed 5 November 2008).
7. Registry ZORA. Porocilo o rezultatih drZavnega programa ZORA v letih 2006 in 2007 [Report on the results of the national screening programme in 2006 and 2007]. Available at: http://www.onko-i.si/zora/00za-izvajalce/ aktualno/Zora-porocilo-2006-2007.pdf (last accessed 5 November 2008).
8. von Krogh G. Management of anogenital warts (condylomata acuminata). Eur J Dermatol 2001;11:598-603. (Pubitemid 33044469)
9. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364:1757-1765
10. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-278
11. Myers ER, McCrory DC, Nanda K, et al. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000;151:1158-1171
12. Kulasingam SL, Benard S, Barnabas RV, et al. Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: a cost-effectiveness analysis. Cost Eff Resour Alloc 2008;6:4.
13. Canfell K, Barnabas R, Patnick J, Beral V. The predicted effect of changes in cervical screening practice in the UK: results from a modelling study. Br J Cancer 2004;91:530-536
14. Bergeron C, Largenon L, McAllister R, et al. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France. Int J Technol Assess Health Care 2008;24:10-19.
15. Szucs TD, Largenon N, Dedes KJ, et al. Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland. Curr Med Res Opin 2008;24:1473-1483
16. Institute of Public Health of the Republic of Slovenia. Available at: http:// www.ivz.si/ (last accessed 10 November 2008).
17. Mitchell MF, Schottenfeld D, Tortolero-Luna G, et al. Colposcopy for the diagnosis of squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 1998;91:626-631 (Pubitemid 28153058)
18. Nanda K, McCrory DC, Myers ER, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000;132:810-819
19. Ursic Vrscaj M., Rakar S, Kovacic J, et al. Priporocila za odkrivanje, zdravljenje in nadzor bolnic s predrakavimi spremembami maternicnega vratu. [Recommendations for the detection, treatment and control of patients with precancerous lesions of the uterine cervix], Ljubljana, 2000, 1-24.
20. Urssics Vrsscsaj M., Rakar S, Mozsina A, Kobal B, Takacs I, Deisinger D. Smernice za celostno obravnavo zsensk s predrakavimi spremembami maternicsnega vratu. [Guidelines for the management of women with cervical cytological abnormalities] Ljubljana, 2006, 1-32.
21. Lomsek M, Rakar S, Kobal B. Zdravljenje prekanceroz maternicnega vratu-analiza podatkov zdravljenih bolnic na ginekolosk kliniki v Ljubljani v obdobju 1996-2000. [Treatment of precancerous lesions of the uterine cervix-data analysis of patients treated at gynaeacological clinic in Ljubljana from 1996 to 2000] Zdrav Vest 2003;72(Suppl II):147-150
22. Ursic Vrscaj M, Rakar S, Mozina A, et al. Rak maternicnega vratu pri zenskah, ki so hodile na ginekoloske preglede-analiza podatkov, zbranih v Sloveniji v letu 2003. [Cervical cancer in women who attended screening-analysis of data gathered in 2003]. Onkologija 2004;VIII(2).
23. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-1927
24. Clifford GM, Rana RK, Franceschi S, et al. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1157-1164
25. Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta- analysis. Br J Cancer 2003;89:101-105
26. Health Insurance Institute of Slovenia. Average prices of health services valid from 1st Jul 2008. Available at: http://www.zzzs.si/zzzs/pao/izvajalci. nsf/o/ 6562A3A7841A5861C125747F0011BF8E 2008 (last accessed 14th November 2008).
27. Institute of Public Health of the Republic of Slovenia. Podlage za razsiritev programa cepljenja s cepljenjem ciljnih skupin proti Humanim virusom papiloma. Interno porocilo. [Basis for the extension of vaccination programme by vaccinating targeted groups against Human Papillomavirus. Internal report], Ljubljana, 2008.
28. Cancer Registry of Slovenia: Available at: http://www.onko-i.si/sl/ dejavnosti/ epidemiologija-in-register-raka/registri-raka/register-raka-za- slovenijo/ (last accessed 10 November 2008).
29. Ursic-Vrscaj M, Rakar S, Mozina A, et al. Clinical audit of patients with cervical cancer in Slovenia. Data analysis from 2003-2006. Eur J Gynaecol Oncol 2008;29:628-632
30. Bos JM, Postma MJ, Annemans L. Discounting health effects in pharmacoeconomic evaluations: current controversies. Pharmacoeconomics 2005;23:639-649
31. Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009;302:750-757
32. Weinstein MC. Recent developments in decision-analytic modelling for economic evaluation. Pharmacoeconomics 2006;24:1043-1053
33. Techakehakij W, Feldman RD. Cost-effectiveness of HPV vaccination compared with Pap smear screening on a national scale: a literature review. Vaccine 2008;26:6258-6265
34. Koulova A, Tsui J, Irwin K, et al. Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008. Vaccine 2008;26:6529-6541
35. Olsson SE, Villa LL, Costa RL, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007;25:4931-4939
36. Schiller JT, Castellsague X, Villa LL, Hildesheim A. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 2008;26(Suppl 10): K53-61.
37. Adams M, Jasani B, Fiander A. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening. Vaccine 2007;25:3007-3013